Using site-directed mutagenesis, we have undertaken a study of a potential IGF-binding site in the C-terminal domain of rat IGFBP-5, lying close to or within a previously described heparin-binding domain (residues 201-218) in this protein. After analysis of binding activity using three different methods -ligand blotting, solution phase equilibrium binding and biosensor measurement of real-time on-and off-rates -we report that the mutation of two highly conserved residues within this region (glycine 203 and glutamine 209) reduces the affinity of the binding protein for both IGF-I and IGF-II, while having no effect on heparin binding. In addition, we confirm that mutation of basic residues within the heparin-binding domain (R201L, K202E, K206Q and R214A) results in a protein that has attenuated heparin binding but shows only a small reduction in affinity for IGF-I and -II. Previous findings have described the reduction in affinity of IGFBP-5 for IGFs that occurs after complexation of the binding protein with heparin or other components of the extracellular matrix (ECM) and have postulated that such an interaction may result in conformational changes in protein structure, affecting subsequent IGF interaction. Our data suggesting potential overlap of heparin-and IGF-binding domains argue for a more direct effect of ECM modulation of the affinity of IGFBP-5 for ligand by partial occlusion of the IGF-binding site after interaction with ECM.
INTRODUCTION
The pleiotropic actions of insulin-like growth factors (IGFs) are mediated by binding to and activating type 1 IGF receptors, which are found on the surface of most cell types (reviewed in Butler et al. 1998) . In turn, the bioavailability of IGFs is regulated by a family of six IGF-specific binding proteins (IGFBPs) that form high-affinity complexes with both IGF-I and IGF-II (reviewed in Clemmons 1997) . The affinity constants of the IGFBPs are between 2-and 50-fold greater for binding IGFs than that of the IGF type 1 receptor, and they can modulate IGF action by preventing the insulin-like effects of IGFs, controlling the half-life of IGFs in blood, acting as carrier proteins for IGFs and determining the distribution of IGFs between tissues and extracellular fluids. The affinity of IGFBPs for IGFs can be controlled by phosphorylation, glycosylation and specific proteolysis of the binding proteins (Conover 1995) .
Several lines of evidence, including mutational analyses, have shown that there is a major IGF-binding site in the conserved N-terminal domain of IGFBPs (Hobba et al. 1996 , 1998 , Kalus et al. 1998 . In addition, deletion analysis in the C-terminus of bovine IGFBP-2 has identified a critical region between amino acids 222-236 of IGFBP-2 that is involved in binding IGFs . The corresponding amino acids in IGFBP-5 lie within a sequence that is rich in basic amino acids (between Arg 201 and Arg 218 ). Amino acid substitution and peptide competition experiments have demonstrated that this site is also involved in the binding of IGFBP-5 to both heparin and extracellular matrix (ECM) (Arai et al. 1996 .
Initially, it would appear surprising that the 201-218 region of IGFBP-5 may also be involved in binding IGFs, as a recent study has shown that mutation of at least 9 of the 10 basic amino acids in this region had no effect on IGF-I binding (Parker et al. 1998) . Nevertheless, alignment of amino acid sequences for all six binding proteins from several species revealed that there are two completely conserved non-basic amino acids (Gly 203 and Gln 209 in rIGFBP-5) within this region (Fig. 1 ). As this conservation suggested an important function for these amino acids, we decided to mutate them, to assess whether they could be involved in IGF binding. These two mutants of rIGFBP-5 are called G203K and Q209A; in addition, we have made a third mutant, Hep-, which has mutations in four of the flanking basic amino acids, previously shown by others (Parker et al. 1998) to be involved in heparin binding (R201L, K202E, K206Q, R214A). We have previously reported that G203K and Q209A have approximately eight-and sixfold reductions in affinity for hIGF-I, respectively (Bramani et al. 1999) . We now extend these studies to include binding to IGF-II and heparin, using IGF and heparin ligand blotting, solution-phase IGF-binding assays and biosensor real-time analysis of binding kinetics. Here, we report that the reduction in binding to IGF-II for both G203K and Q209A is similar to that seen for IGF-I, and that these mutations in non-basic amino acids had little or no effect on heparin binding. Conversely, mutation of the four basic amino acids in Hep-had a deleterious effect on heparin binding, while retaining wild-type-like affinities for binding IGFs, which is in agreement with previous work of others (Parker et al. 1998) . The implications of these findings for IGFBP-5 interaction with both IGFs and ECM are discussed.
MATERIALS AND METHODS

Site-directed mutagenesis
The full-length cDNA for rIGFBP-5 in pGEM-7zf (Promega), containing both initiator and signal peptide, was kindly provided by Dr S Guenette, John Wayne Cancer Institute, Los Angeles, CA, USA. Site-directed mutagenesis to produce G203K and Q209A was performed as described previously (Bramani et al. 1999) . For the Hep-mutations (R201L, K202E, K206Q, R214A), the mutagenic oligonucleotides used were 5 -CCTGCCCAACTG TGACCTCGAGGGATTCTACCAGAGAAAGC AGTGCAAG-3 and 5 -AGCAGTGCAAGCCT TCTGCAGGCCGCAAACGTGGCAT-3 (MWG Biotech UK Ltd, Milton Keynes, Bucks, UK), which created unique XhoI and PstI restriction sites, respectively. After mutagenesis, the DNA was maxi-prepped using the Qiagen Plasmid Maxi Prep Kit (Crawley, West Sussex, UK) and manually sequenced using the T7 Sequenase version 2.0 DNA sequencing kit (Amersham Life Sciences, Little Chalfont, Bucks, UK), which verified that the correct mutations were present.
Baculovirus expression
Expression of recombinant IGFBPs in the insect cell-baculovirus system was carried out using the Bac-to-Bac system (Gibco-BRL, Paisley, Renfrewshire, UK) to produce recombinant virus. Conditions for expression were identical to those described previously (Bramani et al. 1999) .
IGF-I and -II ligand blotting and western blotting
Proteins were electrophoresed on 12% acrylamide SDS-PAGE gels under non-reducing conditions and subsequently transferred to nitrocellulose membranes. Ligand blots were performed according to the method described by Hossenlopp et al. (1986) , using IGF-I or -II (GroPep) radiolabelled to a specific activity of approximately 100 µCi/µg. Western blots with an 'in-house' sheep anti-rat IGFBP-5 antiserum were performed as described previously (Bramani et al. 1999) and were used to monitor protein loading during ligand and heparin blotting experiments.
Heparin ligand blotting
The method used was adapted from that described by Grulich-Henn et al. (1998) for detection of serum IGFBPs by blotting with biotinylated IGF-I. Approximately 27·5 ng of each protein was subjected to electrophoresis on 12·5% SDS-PAGE under nonreducing conditions and subsequently transferred onto Hybond-C Extra membranes (Amersham). After transfer, filters were dried at 37 C for 5 min. The membranes were then washed with 3% NP40 Tris-saline (10 mM Tris, 0·15 M NaCl pH 7·4) for 30 min and blocked with 3% BSA-Tris-saline for 2 h at room temperature with shaking, then incubated overnight with a 1:2000 dilution of heparinalbumin-biotin (Sigma) in 1% BSA-0·1% Tween-20-Tris-saline at 4 C. The membranes were washed (3 15 min) with 1% BSA-0·1% Tween-20-Trissaline and then incubated with a 1 : 2000 dilution of streptavidin-horseradish peroxidase (HRP) conjugate (Boehringer Mannheim, Lewes, E Sussex, UK) in 1% BSA-0·1% Tween-20-Tris-saline for 1 h. Finally, the membranes were washed (3 15 min) with Tris-saline, and bound heparin was detected using the enhanced chemiluminescence (ECL) detection system (Amersham). The membranes were then subjected to densitometric analysis (Molecular Dynamics, Bucks, UK) to measure the binding ratio of each protein. As described for 125 I-IGF ligand blotting, protein loading was monitored by blotting duplicate membranes with anti-IGFBP-5 antisera.
Solution-phase assay of IGFBP activity
Activity of wild-type IGFBP-5, G203K, Q209A and Hep-were assessed in solution by the method described by Conover et al. (1989) . Amounts of wild-type, G203K, Q209A and Hep-proteins were present in assay tubes ( 0·55-7·7ng) such that approximately 20% of added 
Biosensor analysis
Kinetics of wild-type IGFBP-5, G203K, Q209A and Hep-binding to both IGF-I and IGF-II was investigated using a Biacore 2000 system (Biacore AB, Stevenage, Herts, UK). IGF-I and -II were immobilised to the surface of a CM5 sensorchip via N-hydroxy succinimide/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (NHS/ EDC) coupling, in accordance with the manufacturer's instructions. As a control, insulin (which does not bind IGFBP-5) was immobilised to flowcell 1. Each polypeptide was immobilised to a level of 1000 resonance units (RU). Wild-type and mutant IGFBP-5 proteins in baculovirus-conditioned medium were injected simultaneously over all three experimental flowcells at a flow rate of 30 µl/min. Five different concentrations (1·09, 2·18, 4·37, 8·75 and 17·5 nM) of IGFBP-containing culture medium were applied and the regeneration of biosensor chip surface after association and dissociation of binding protein was achieved with sequential 2 2 min pulses of 20 mM HCl. Under these conditions, the sensorchip surface was regenerated without any time-dependent increases in background RU signal. Kinetic values (K on and K off ) were calculated assuming a 1 : 1 stoichiometry of binding between IGF and IGFBP-5 protein(s) and using the BIA evaluation 3.0 software provided by the manufacturer.
RESULTS
When we examined the binding of the mutant IGFBP-5 proteins, G203K and Q209A, to both 125 I-IGFs-I and -II by ligand blot analysis, we found that binding was reduced compared with wild-type ( Fig. 2A) . Scanning densitometry of these blots indicated that binding of G203K and Q209A was reduced to approximately 10% of that seen for the wild-type protein for both IGF-I and IGF-II binding (Fig. 2B) . Conversely, the binding of the Hep-mutant to either 125 I-IGF-I or -II was not affected, giving a signal on ligand blots equivalent to that seen for wild-type IGFBP-5. We also examined the affinity of these four proteins in a solution-phase analysis of the IGF-IGFBP interaction (Fig. 3A,  B) . Scatchard analysis derived from binding curves of wild-type IGFBP-5, Hep-, Gly 203 and Gln 209 proteins gave K D values of 0·05, 0·07, 0·3 and 0·21 nM respectively for binding to IGF-I (Fig. 3A) and 0·023, 0·046, 0·066 and 0·134 nM respectively for binding to IGF-II (Fig. 3B ). These data for wild-type rat IGFBP-5 indicate a twofold greater affinity for IGF-II than for IGF-I and agree with the ligand preference reported for human IGFBP-5 (Kiefer et al. 1992) . These data also indicate that the compromised binding of IGF-I and -II to G203K and Q209A detected by ligand blot was also apparent in solution phase, with a six-and threefold reduction in binding of G203K to IGF-I and -II, respectively and a four-and sixfold reduction in Q209A binding to IGF-I and -II, respectively. Although, by ligand blotting, we did not detect any differences in binding 125 I-IGF-I or -II between wild-type IGFBP-5 and the Hep-mutant, solutionphase analysis of binding suggested the Hepprotein had a small (twofold) lower affinity for IGF-II in comparison with the wild-type protein.
As a further confirmation of the IGF-binding properties of these IGFBP-5 mutant proteins, we undertook a biosensor analysis of binding kinetics of the proteins to both IGF-I and IGF-II immobilised to a biosensor surface (Table 1) . This type of analysis gives details of on-and off-rate kinetic constants from which association and dissociation constants can be derived. Again, qualitative differences in the affinity of the four IGFBP-5 proteins for both IGF-I and -II were maintained. Closer inspection of the BiaCore data revealed that the reduction in the affinity of the G203K mutant for IGF-I and -II was due to a substantially (5-10-fold) decreased on-rate, with a much smaller effect at the off-rate for this binding complex. For the Q209A mutant, the compromised affinity of the mutant for IGF-I and -II was manifested as decreased on-rate and increased off-rates; for IGF-I, there was an almost threefold decrease in K on , coupled with a fourfold increase in K off , and for IGF-II the effect was much greater, with a 30-fold decrease in K on , together with a 15-fold increase in K off . Also of interest was the observation that, although the overall affinity (K D ) of the Hep-mutant for IGF-I and -II was similar to that of wild-type IGFBP-5, at the level of rate constants there were apparent differences for the interaction of Hep-with either IGF-I or IGF-II. However, the 8-and 25-fold decreases in K on values for Hep-binding to IGFs-I and -II, respectively, were partly offset by the 14-and 6-fold decreases in K off values obtained for the same binding events. This results in a similar affinity for wild-type IGFBP-5 and Hep-binding to IGF-I and -II. We also note that the absolute values for dissociation constants (K D ) derived by biosensor were two to three orders of magnitude lower than that obtained with the charcoal-based solution phase assays ( Fig. 3 ; see Discussion).
Experiments were also carried out to investigate the heparin-binding properties of our four IGFBP-5 proteins. Using a blotting methodology with a heparin-biotin conjugate and streptavidin-HRP/ECL detection system, we were able to confirm that the Hep-mutant containing mutations at four basic residues important for heparin binding (R201L, K202E, K206Q and R214A) showed greatly reduced heparin binding (Fig. 4) . However, the G203K and Q209A IGF-defective mutants displayed a binding activity for the heparin-biotin conjugate similar to that displayed by the wild-type IGFBP-5. Therefore, within the 201-218 region of IGFBP-5, we have been able partially to assign residues important for IGF binding and different side-chains required for heparin binding. A projected helical structure for this region of the protein (Parker et al. 1998) suggests the juxtaposition of these residues (Fig. 5) , and this, in turn, suggests a putative model to explain the effect of an ECM-IGFBP-5 association on the subsequent affinity for IGF-I and -II (see Discussion).
DISCUSSION
This work has confirmed our previous results that the mutations, G203K and Q209A, in the C-terminal domain rIGFBP-5 lead to a significant loss (four-to tenfold) of binding affinity for IGF-I, as determined by solution-phase assay and ligandblot analysis (Bramani et al. 1999) . We have now extended this study to show that these mutations also affect binding to IGF-II. Ligand blot analysis with 125 I-IGF-II followed by densitometry indicated binding of G203K and Q209A at 10% of that seen for wild-type IGFBP-5, which agreed with the data obtained after ligand-blot analysis with 125 I-IGF-I. However, solution-phase assay with IGF-II indicated a somewhat smaller decrease in affinity -reduced threefold for G203K. Although we did not conduct a systematic analysis of the differences in ligand binding between these two methodologies, such differences have been reported previously (Hobba et al. 1998) . In a similar vein, ligand-blot analysis suggested equivalent binding of labelled IGFs-I and -II by wild-type and Hep-proteins. However, a small difference in affinity between these two proteins was observed with solution-phase analysis of binding using  1. Biacore analysis of kinetic constants for wild-type (Wt) IGFBP-5, Hep-, G203K and Q209A binding to immobilised IGF-I and -II. For further details, see Materials and Methods I-IGF-II (Hep-has a twofold lower affinity for IGF-II). As indicated by Hobba et al. (1998) , it is likely that ligand-blot analysis ranks IGFBPs in order of K off values. This is confirmed by our subsequent Biacore analysis indicating that, of the four mutants, Hep-has the lowest K off value, which then appears, on ligand blots, to have a signal equivalent to the wild-type protein. It is important to note that the K D of our wild-type IGFBP-5, as determined by solution-phase assay, is in agreement with that reported by others using mammalian IGFBP-5 and the yeast expressed protein (Kiefer et al. 1992) , and that the IGFBP-5 doublet produced by transfected insect cells represents a single species with respect to IGF binding, as BiaCore analysis recorded a single association and dissociation event for each recombinant IGFBP-5 protein. In addition, others have observed an IGFBP-5 doublet expressed from human fibroblast cells (Arai et al. 1994a) , demonstrating that this is not specifically a result of expression of IGFBP-5 in insect cells.
IGF-I IGF-II
In a qualitative sense, our biosensor data support the findings of both the ligand-and solution-phase assays of IGF affinity, with major effects of G203K and Q209A binding to IGF-I and -II, and a smaller effect of Hep-interaction with either of the IGFs.
However, although the overall affinity (K D ) of the Hep-mutant for IGF-I and -II was similar to that of wild-type IGFBP-5, the biosensor analysis enabled us to observe specific effects on K on and K off for Hep-. The absolute K D values obtained by biosensor for our four proteins are 100-to 1000-fold lower than those seen in solution phase, and are also lower, by the same order of magnitude, than the affinity constants reported for the human IGFBP-5 interaction with hIGF-I by BiaCore (Kalus et al. 1998) . However, these researchers used biotinylated IGF-I or -II immobilised to streptavidin-coated biosensor chips, together with different conditions for monitoring on-and off-rates. In addition, the homologous interaction system reported by these authors (human IGFs and human IGFBP-5) is different from the system in the current study, in which rat IGFBP-5 proteins were exposed to sensor chips containing directly immobilised human IGF-I or -II. Together, these experimental differences may account for the different results obtained. Interestingly, and supportive of this argument, are the findings of Hobba et al. (1998) , who examined the heterologous interaction of bovine IGFBP-2 with immobilised human IGF-I and -II. In their study, conditions of ligand immobilisation and binding analysis were similar to those described in the current work and, accordingly, these authors reported kinetic constants of the same order as we have reported here. Notwithstanding these arguments, our biosensor data fully support our ligand-blotting and solution-phase data indicating compromised binding of G203K and Q209A to both IGF-I and IGF-II, and only a relatively minor effect on overall affinity for the Hep-mutant.
Others have found a far greater reduction (up to 80-fold) in IGF-II affinity when the equivalent amino acids (222-236) were deleted from bovine IGFBP-2 . This may reflect differences in the C-terminus between IGFBP-5 and -2 with respect to binding IGF-II or, alternatively, the loss of both of these residues, as occurs with the IGFBP-2 truncation, may have a cumulative effect that results in a greater reduction in binding. In fact, these researchers also presented evidence that smaller C-terminal truncations affected the specificity of IGF binding, suggesting that other residues downstream in the amino acid sequence may be involved in differential recognition of IGF-I and -II . Also, Kalus et al. (1998) concluded that association of IGFs with IGFBP-5 was principally determined by binding to the N-terminal domain, and that the role of the C-terminal domain was to decrease the rate of dissociation. This conclusion may have been premature, as our biosensor data show that the reduced affinity for G203K results principally from a decreased rate of association.
The fact that Gly 203 and Gln 209 in the C-terminus of IGFBP-5 are completely conserved between all six binding proteins from all species sequenced to date (Fig. 1) suggests that they may have a conserved function in IGFBP biology. From this work, it would appear that, for IGFBP-5 at least, one of the functions of these residues involves IGF binding. This is of major significance when one considers that, in IGFBP-5 and -3, these two residues lie in the middle of a stretch of basic amino acids that have previously been shown to be involved in binding to heparin and to components of the ECM (Arai et al. 1996 . Other functions ascribed to this region in IGFBP-5 include binding to the acid-labile subunit (Twigg et al. 1998) , to the putative IGFBP-5 receptor (Andress 1998) , and to plasminogen activator inhibitor-I (Nam et al. 1997) . It has even been postulated that this sequence has strong homology to nuclear localisation signals (Schedlich et al. 1998) and the DNA-binding domains of several transcription factors (Turner & Tjian 1989 , Schedlich et al. 1998 .
Heparin ligand analysis clearly demonstrated that the binding of mutants G203K and Q209A was not compromised (Fig. 4) . As a control, we also decided to study some of the flanking basic amino acids, mutation of which had been shown by others to affect heparin binding (Arai et al. 1996) while not affecting IGF binding (Parker et al. 1998) . However, our biosensor data for the Hep-mutant (R201L, K202E, K206Q, R214A) demonstrated specific effects at the level of rate constants, which would not have been observed previously because the overall affinity is similar to that of wild-type IGFBP-5. On the basis of this finding, we would suggest that, in addition to the major role that these four basic amino acids have in heparin binding, they may also have a more minor role in IGF binding. Therefore, it would appear that, in the linear sequence, basic amino acids involved in heparin binding, and possibly IGF binding, are interspersed with non-basic amino acids that are clearly involved in IGF binding. A helical-wheel prediction of the 201-218 region of IGFBP-5, places Gly 203 adjacent to important ECM-binding residues, whereas Gln 209 is flanked by two further basic residues elsewhere in the wheel (Fig. 5) . This demonstrates that there may be overlap between IGF and ECM binding sites in the C-terminus of IGFBP-5.
As Gly 203 and Gln 209 are conserved in all six binding proteins, whereas the C-terminal heparin binding sequence is only common to IGFBP-5 and -3, this may mean that the IGF-binding function of this region predates heparin binding. Therefore, the heparin/ECM binding sequences in IGFBP-5 and -3 may have evolved later, to provide greater regulation of an increasingly complex IGF system. Whether this regulation serves to potentiate or to inhibit the effects of IGFs is unresolved, although experiments from other laboratories clearly indicate that heparin/ECM-bound IGFBP-5 has between an 8-and a 17-fold reduced affinity for binding IGF-I (Andress & Birnbaum 1992 , Jones et al. 1993 , Arai et al. 1994b ). These reduced affinities may be crucial in obtaining the correct balance between soluble IGFs available for binding IGF receptors, and ECM-bound IGFBP-IGF complexes.
One explanation offered for the reduced affinity of ECM-bound IGFBP-5 for IGF-I is that heparin binding might induce a conformational change in IGFBP-5, which alters an IGF-binding domain elsewhere in the protein (Arai et al. 1996) . On the basis of the work reported here, in which we indicate a potential overlap between heparin-and IGF-binding sites in the C-terminal domain of rat IGFBP-5, we propose an alternative, more direct, model in which heparin or ECM binding to the basic amino acids in the 201-218 region of IGFBP-5 may physically interfere with the subsequent interaction with IGFs. It is possible, however, that this region of the IGFBP-5 protein does not exist as a helical structure, and that there is a spatial separation of Gly 203 , Gln 209 and the important basic residues. Further advances in this area will be achieved by the careful structural and functional analysis of heparin-IGFBP-5-IGF complexes.
